Pulmonology

These data suggest vaping poses potential threats to the development of the brain and organs, with teenagers being a predominant target due to surges in use.

This segment of the latest Lungcast episode featured a discussion over the ALA’s State of the Air Report and the impacts of particle pollution.

A retrospective study challenges preoperative withholding of GLP-1 RAs in diabetes patients undergoing surgery, citing no increased risk of postoperative respiratory complications.

Thoracic ultrasound examination may be applicable as a screening method for interstitial lung disease in patients with RA and respiratory symptoms.

In this Q&A, Kathuria explains the current state of smoking cessation programs and how health care providers can help patients combat their tobacco dependence.

In the latest Lungcast, Drs. McCurry and Valapour answered several questions on the candidacy of post-infectious COVID-19 patients for lung transplantation and on long COVID.

During this segment of Lungcast, Valapour and McCurry discussed recent changes made to lung allocation scores as well as the topic of graft rejection.

AHN's AI-ILD clinic provides collaborative care, uniting pulmonology and rheumatology specialists for efficient treatment of ILD.

In this Month in Review article for March, news on topics such as asthma and the impacts of pollution in the pulmonology field were highlighted.

These data may have impactful clinical and health policy implications, given that hospitalizations for CAP are known to be common and given the frequency of incorrect diagnoses.

A recap of the biggest FDA news and decisions in cardiovascular medicine from the first 3 months of 2024, with commentary on recent announcements by Deepak Bhatt, MD, MPH, MBA.

New data show COPD and IPF, among other interstitial lung diseases, are more significantly associated with poor 30-day outcomes from COVID-19 than asthma.

The investigators seek to replicate the data in a future randomized control trial, and they hope to compare biofeedback to different therapies such as pulmonary rehabilitation.

The approval marks the first and only once-daily single-tablet combination therapy for patients with pulmonary arterial hypertension.

A new study suggests patients with either rheumatoid arthritis or osteoarthritis may be at a higher genetic susceptibility to develop COPD.

The results of this meta-analysis highlight the prevalence of subclinical pulmonary tuberculosis among adult patients, given the poor clinical definition of the condition.

New data from NIH investigators show acute respiratory distress syndrome from COVID-19 infection may trigger heart inflammation in patients.

These findings highlight the gaps in care among patients with cancer with regard to smoking assessments.

On March 15, 2024, the FDA approval of fluticasone propionate nasal spray marks the first approval in agency history for treatment of chronic rhinosinusitis without nasal polyps.

On March 07, 2024, Boehringer Ingelheim announced it would be instituting a $35 per month out-of-pocket cost cap for its portfolio of inhaler products, with this cap going into effect on June 01, 2024.

This analysis was conducted to address previous suspicions on the results of pulse oximetry among patients with skin of color.

These mental health outcomes were seen among those with self-reported COPD and asthma, though not among individuals with objective diagnoses based on spirometry.

This analysis looked into whether rapid respiratory virus testing in patients with suspected acute respiratory infection was linked to such outcomes as antibiotic use decrease and hospitalization.

In the final part of our 3-part series, our panel of experts discuss what their fields and its leaders could do to make sure this lack of diversity in trials does not continue. These responses are highlighted in the following video and transcribed below.

In part 2 of our 3-part series on the impact of clinical trials lacking diversity, we are spotlighting responses to our second question, which addresses how the previously established lack of diversity in clinical trials has had a direct effect on the development and application of new therapies or devices in real-world settings.

In part 1 of our 3-part series on the impact of clinical trials lacking diversity, we are spotlighting responses to our first question, which sought to encapsulate the perspectives of our group of experts on how a historic lack of diversity in clinical trials has manifested itself in today’s care of patients from diverse backgrounds.

This article serves as a landing page for our 3-part series spotlighting how a lack of diversity in clinical trials has had a deleterious downstream effect on real-world care for people of color in the US, with perspective from experts across more than half a dozen specialties.

The MANDARA trial results, published in NEJM, show benralizumab's noninferiority to mepolizumab in eosinophilic granulomatosis with polyangiitis, with potential for oral glucocorticoid discontinuation.

The FDA’s decision is planned for June 2024, and follows the successful results of the BOREAS and NOTUS trials.

Additional research may be necessary to look at the sequence of epinephrine administration and advanced airway management in settings in which alternative epinephrine administration strategies are utilized.